This study shows sirt1's protective effect against albumin-related podocyte damage, indicating its role in managing CKD.
Background and purpose: This study investigates the protective effects of sirt1 on albumin-induced podocyte damage, focusing on the regulatory role of HIF-1a. Podocyte injury contributes significantly to proteinuria, a marker of chronic kidney disease (CKD) progression. Understanding the sirt1/HIF-1a pathway may provide insights into novel therapeutic strategies for CKD. Materials and methods: Cultured mouse podocytes were divided into control, albumin-induced, sirt1 agonist, and sirt1 inhibitor groups. RTqPCR was used to evaluate the expression of sirt1 and HIF-1a mRNA. Protein levels of Nephrin, podocalyxin, and TRPC6 were assessed through Western blot and immunofluorescence techniques to determine podocyte damage. Results: The albumin-induced group showed decreased Sirt1 and increased HIF-1a levels, while sirt1 agonists reversed these changes, indicating that the kidney protective effect. In contrast, sirt1 inhibitors worsened podocyte injury. Western blot and immunofluorescence confirmed a significant reduction in Nephrin and podocalyxin and an increase in TRPC6 protein expression in albumin-treated groups, which was mitigated by sirt1 activation. Conclusions: Sirt1 protects against albumin-induced podocyte damage by modulating HIF-1a, suggesting its potential as a therapeutic target for proteinuria and CKD management. This study provides a foundational understanding of sirt1's role in podocyte protection and highlights the need for further research to explore its clinical applications in preventing CKD progression.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: